GLP-1 receptor agonists, CKD, and eGFR trajectory - Authors' reply

Affiliations

¹ Providence Health Care, University of Washington, Spokane, WA 99204, USA. Electronic address: katherine.tuttle@providence.org.
² Eli Lilly and Company, Indianapolis, IN, USA.
³ Division of Nephrology and Hypertension, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa.
⁴ Albany Medical Center Division of Community Endocrinology, Albany, NY, USA.

Comment

Katherine R Tuttle et al. Lancet Diabetes Endocrinol. 2018 Oct.

. 2018 Oct;6(10):765.

doi: 10.1016/S2213-8587(18)30239-0.

¹ Providence Health Care, University of Washington, Spokane, WA 99204, USA. Electronic address: katherine.tuttle@providence.org.
² Eli Lilly and Company, Indianapolis, IN, USA.
³ Division of Nephrology and Hypertension, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa.
⁴ Albany Medical Center Division of Community Endocrinology, Albany, NY, USA.

No abstract available

Comment on

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT. Tuttle KR, et al. Lancet Diabetes Endocrinol. 2018 Aug;6(8):605-617. doi: 10.1016/S2213-8587(18)30104-9. Epub 2018 Jun 14. Lancet Diabetes Endocrinol. 2018. PMID: 29910024 Clinical Trial.
GLP-1 receptor agonists, CKD, and eGFR trajectory.
van Baar MJB, van Raalte DH, Muskiet MHA. van Baar MJB, et al. Lancet Diabetes Endocrinol. 2018 Oct;6(10):764-765. doi: 10.1016/S2213-8587(18)30241-9. Lancet Diabetes Endocrinol. 2018. PMID: 30266180 No abstract available.